Investigating the role of a protein in kidney damage related to nephrotic syndrome
The Role of Proprotein-convertase-subtilisin/Kexin-type 9 in Kidney Damage in Nephrotic Syndrom
This study is trying to see if a protein called PCSK9 is linked to kidney damage and high cholesterol in people with nephrotic syndrome.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 75 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Kolding Sygehus Academic / other |
| Locations | 1 site (Kolding) |
| Trial ID | NCT06373913 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with nephrotic syndrome (NS) and associated hyperlipidemia. It will compare plasma levels of PCSK9 between patients with NS and kidney-healthy controls, as well as assess the correlation between PCSK9 levels and the degree of proteinuria. Additionally, kidney tissue biopsies will be analyzed to evaluate PCSK9 expression in patients with NS. The study seeks to understand how PCSK9 contributes to hyperlipidemia and kidney damage in this patient population.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older who are admitted to the Medical Department or Medical Emergency Department with nephrotic syndrome.
Not a fit: Patients who are currently receiving treatment with PCSK9 inhibitors or have conditions that limit their ability to participate may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of hyperlipidemia in patients with nephrotic syndrome, potentially reducing morbidity and mortality.
How similar studies have performed: While the role of PCSK9 in nephrotic syndrome is being explored, this specific investigation is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years old * Patients admitted to the Medical Department and/or the Medical Emergency Department, Kolding Sygehus. Exclusion Criteria: * Refusal to give informed consent * Treatment with PCSK9 inhibitors * Any acute or chronic condition that would limit the ability of the patient to participate in the study * Control group: proteinuria
Where this trial is running
Kolding
- Kolding Sygehus, Lillebælt Hospital — Kolding, Denmark (Recruiting)
Study contacts
- Study coordinator: Rikke Z Langkilde, MD, phd
- Email: rikke.zachar.langkilde@rsyd.dk
- Phone: 004576362554
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.